- Do Steroid Shots Help Ease Back Pain? Experts Weigh In
- Americans Who’ve Become Caregivers Rose by a Third in 10 Years
- Epstein-Barr Virus Might Help Trigger Cancer After Kidney Transplant
- Seniors, Could Working Later in Life Be Healthy?
- Zoo Workers Battle Grief When Animals in Their Care Die
- Number Infected Now 24 in Texas County Measles Outbreak
- Depression Can Speed Onset of Chronic Illnesses, Study Finds
- RFK Jr. Confirmed as Health Secretary in Near Party-Line Vote
- Belly Fat, Diabetes and Drinking Doubles Liver Disease Risk
- Experts Warn Marijuana Ads Are Reaching Kids Through Social Media
Tretten Approved for Genetic Clotting Disorder

Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.